These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38768736)

  • 21. Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
    Xie O; Cisera K; Taylor L; Hughes C; Rogers B
    Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):57. PubMed ID: 33256752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic Exposure in the Community and Resistance Patterns of Escherichia coli Community-Acquired Bloodstream Infection.
    Gottesman BS; Shitrit P; Katzir M; Chowers M
    Isr Med Assoc J; 2018 Jun; 20(6):382-384. PubMed ID: 29911761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Risk Factors, Antimicrobial Resistance Trends and Occurrence of blaTEM, bla SHV and blaCTX M in Escherichia coli Causing Bacteremia.
    Sinha R; Kamath S; M Shenoy S
    Infect Disord Drug Targets; 2016; 16(2):95-100. PubMed ID: 26707079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial Resistance Trends of
    Milano A; Sulejmani A; Intra J; Sala MR; Leoni V; Carcione D
    Microb Drug Resist; 2022 Jan; 28(1):63-72. PubMed ID: 34520265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteraemia due to AmpC β-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes.
    Zhang Q; Zhang W; Li Z; Bai C; Li D; Zheng S; Zhang P; Zhang S
    Diagn Microbiol Infect Dis; 2017 Jul; 88(3):247-251. PubMed ID: 28434898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic guidelines coupled with selective reporting of antibiograms.
    Michelangeli C; Girard-Lamoulere D; Assi A; Della Guardia M; Roger PM
    Infect Dis Now; 2021 Feb; 51(1):61-66. PubMed ID: 32360395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical features and antibiotic resistance of Escherichia coli bloodstream infections in children].
    Li S; Guo L; Liu L; Dong F; Liu G
    Zhonghua Er Ke Za Zhi; 2016 Feb; 54(2):150-3. PubMed ID: 26875468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for gentamicin-resistant E. coli in children with community-acquired urinary tract infection.
    Roldan-Masedo E; Sainz T; Gutierrez-Arroyo A; Gomez-Gil RM; Ballesteros E; Escosa L; Baquero-Artigao F; Méndez-Echevarría A
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2097-2102. PubMed ID: 31359255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of selective reporting of antibiotic susceptibility test results on the appropriateness of antibiotics chosen by French general practitioners in urinary tract infections: a randomised controlled case-vignette study.
    Bourdellon L; Thilly N; Fougnot S; Pulcini C; Henard S
    Int J Antimicrob Agents; 2017 Aug; 50(2):258-262. PubMed ID: 28577933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
    Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
    Senard O; Lafaurie M; Lesprit P; Nguyen Y; Lescure X; Therby A; Fihman V; Oubaya N; Lepeule R
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):121-129. PubMed ID: 31512147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
    Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
    Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling the implementation of narrow versus broader spectrum antibiotics in the empiric treatment of E. coli bacteraemia.
    Khurana MP; Curran-Sebastian J; Bhatt S; Knight GM
    Sci Rep; 2024 Jul; 14(1):16986. PubMed ID: 39043719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.